16156-57-3

Basic information

• Product Name: Cyclopentanol, methanesulfonate
• Synonyms: cyclopentyl methanesulfonate;methanesulfonic acid cyclopentyl ester;Cyclopentanol,methanesulfonate;Methansulfonsaeure-cyclopentylester;cyclopentyl mesylate
• CAS NO: 16156-57-3
• Molecular Formula: C6H12O3S
• Molecular Weight: 164.225
• Mol File: 16156-57-3.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Cyclopentanol, methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopentanol, methanesulfonate(16156-57-3)
• EPA Substance Registry System: Cyclopentanol, methanesulfonate(16156-57-3)

Safety Data

• Hazardous Substances Data: 16156-57-3(Hazardous Substances Data)

Upstream product

• 96-41-3 Cyclopentanol 
• 124-63-0 methanesulfonyl chloride 
• 120-92-3 cyclopentanone 

Downstream Products

• 827-55-4 p-cyclopentyltoluene 
• 37438-02-1 1-cyclopentyl-3-methylbenzene 
• 37438-01-0 1-cyclopentyl-2-methylbenzene 
• 124-18-5 decane 
• 112-95-8 icosane 
• 2883-12-7 3-cyclopentyl-1-phenylpropane 
• 197573-17-4 4-cyclopentyloxy-3-methoxy-benzaldehyde 
• 67387-76-2 3-cyclopentyloxy-4-methoxybenzylaldehyde 
• 141772-32-9 2-fluoro-4-chloro-5-cyclopentyloxyaniline 
• 143661-65-8 2-fluoro-5-cyclopentyloxyaniline 
• 849662-59-5 [4-(4-cyclopentyl-piperazin-1-yl)-phenyl]-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone 
• 700-88-9 cyclopentylbenzene 
• 75-75-2 methanesulfonic acid 
• 96-41-3 Cyclopentanol 

Relevant articles and documents

-

-

CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS

The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.

POLYCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USES THEREOF

Disclosed in the present invention are polycyclic derivatives as represented by general formula (I), the preparation method thereof, pharmaceutical compositions containing the derivatives and uses thereof as therapeutical agents, especially the GPR40 agonist and in preparation of drugs for treating diseases like diabetes and metabolic disorders, etc., wherein each substituent in the general formula (I) has the same definition as in the description.